Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 102

1.

Acute coronary thrombolysis with recombinant human tissue-type plasminogen activator: initial patency and influence of maintained infusion on reocclusion rate.

Verstraete M, Arnold AE, Brower RW, Collen D, de Bono DP, De Zwaan C, Erbel R, Hillis WS, Lennane RJ, Lubsen J, et al.

Am J Cardiol. 1987 Aug 1;60(4):231-7.

PMID:
3113222
2.

Evaluation of a prolonged infusion of recombinant tissue-type plasminogen activator (Duteplase) in preventing reocclusion following successful thrombolysis in acute myocardial infarction.

Kalbfleisch J, Thadani U, LittleJohn JK, Brown G, Magorien R, Kutcher M, Taylor G, Maddox WT, Campbell WB, Perry J Jr, et al.

Am J Cardiol. 1992 May 1;69(14):1120-7.

PMID:
1575179
4.

[Intravenous infusion of recombinant tissue-type plasminogen activator (rt-PA) and urokinase in acute myocardial infarct: intermediate results of the G.A.U.S. study (German Activator Urokinase Study)].

Neuhaus KL, Tebbe U, Gottwik M, Weber MA, Feuerer W, Niederer W, Haerer W, Praetorius F, Grosser KD, Huhmann W, et al.

Klin Wochenschr. 1988;66 Suppl 12:102-8. German.

PMID:
3126339
6.

Improved thrombolysis with a modified dose regimen of recombinant tissue-type plasminogen activator.

Neuhaus KL, Feuerer W, Jeep-Tebbe S, Niederer W, Vogt A, Tebbe U.

J Am Coll Cardiol. 1989 Nov 15;14(6):1566-9.

7.

Open, noncontrolled dose-finding study with a novel recombinant plasminogen activator (BM 06.022) given as a double bolus in patients with acute myocardial infarction.

Tebbe U, von Essen R, Smolarz A, Limbourg P, Rox J, Rustige J, Vogt A, Wagner J, Meyer-Sabellek W, Neuhaus KL.

Am J Cardiol. 1993 Sep 1;72(7):518-24.

PMID:
8362764
8.

Intravenous recombinant tissue plasminogen activator (rt-PA) and urokinase in acute myocardial infarction: results of the German Activator Urokinase Study (GAUS).

Neuhaus KL, Tebbe U, Gottwik M, Weber MA, Feuerer W, Niederer W, Haerer W, Praetorius F, Grosser KD, Huhmann W, et al.

J Am Coll Cardiol. 1988 Sep;12(3):581-7.

PMID:
3042835
10.

Coronary arterial thrombolysis with combined infusion of recombinant tissue-type plasminogen activator and urokinase in patients with acute myocardial infarction.

Topol EJ, Califf RM, George BS, Kereiakes DJ, Rothbaum D, Candela RJ, Abbotsmith CW, Pinkerton CA, Stump DC, Collen D, et al.

Circulation. 1988 May;77(5):1100-7.

PMID:
2966017
11.
12.
15.

More rapid, complete, and stable coronary thrombolysis with bolus administration of reteplase compared with alteplase infusion in acute myocardial infarction. RAPID Investigators.

Smalling RW, Bode C, Kalbfleisch J, Sen S, Limbourg P, Forycki F, Habib G, Feldman R, Hohnloser S, Seals A.

Circulation. 1995 Jun 1;91(11):2725-32.

17.

Sequential combination thrombolytic therapy for acute myocardial infarction: results of the Pro-Urokinase and t-PA Enhancement of Thrombolysis (PATENT) Trial.

Zarich SW, Kowalchuk GJ, Weaver WD, Loscalzo J, Sassower M, Manzo K, Byrnes C, Muller JE, Gurewich V.

J Am Coll Cardiol. 1995 Aug;26(2):374-9.

18.

Coronary thrombolysis with recombinant tissue-type plasminogen activator: patency rate and regional wall motion after 3 months.

Jang IK, Vanhaecke J, De Geest H, Verstraete M, Collen D, Van de Werf F.

J Am Coll Cardiol. 1986 Dec;8(6):1455-60.

PMID:
3097099
19.

Coronary patency after intravenous infusion of recombinant tissue-type plasminogen activator in acute myocardial infarction.

Brower RW, Arnold AE, Lubsen J, Verstraete M.

J Am Coll Cardiol. 1988 Apr;11(4):681-8.

PMID:
3127450
20.

Six- and twelve-month follow-up of the phase I Thrombolysis in Myocardial Infarction (TIMI) trial.

Dalen JE, Gore JM, Braunwald E, Borer J, Goldberg RJ, Passamani ER, Forman S, Knatterud G.

Am J Cardiol. 1988 Aug 1;62(4):179-85. Erratum in: Am J Cardiol 1988 Nov 15;62(16):1151.

PMID:
3135737

Supplemental Content

Support Center